Northland Securities Sticks to Its Buy Rating for BioLife Solutions (BLFS)

In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on BioLife Solutions, with a price target of $34.00.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Byrnes is an analyst with an average return of -4.9% and a 34.96% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as BioLife Solutions, Indivior, and MiMedx Group.

In addition to Northland Securities, BioLife Solutions also received a Buy from Lake Street’s Thomas Flaten in a report issued today. However, on the same day, TipRanks – xAI reiterated a Hold rating on BioLife Solutions (NASDAQ: BLFS).

Based on BioLife Solutions’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $18.79 million and a net profit of $3.54 million. In comparison, last year the company had a net profit of $12.46 million

Based on the recent corporate insider activity of 125 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BLFS in relation to earlier this year. Most recently, in December 2025, Sarah Aebersold, the CHRO of BLFS sold 713.00 shares for a total of $17,439.98.